Metaxalone Patent Expiration
Metaxalone was first introduced by King Pharmaceuticals Research And Development Llc A Sub Of Pfizer Inc
Metaxalone Patents
Given below is the list of patents protecting Metaxalone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Metaxalone | US11918559 | Reduced dose metaxalone formulations | Jul 29, 2039 | Primus Pharms |
| Skelaxin | US7122566 | Metaxalone products, method of manufacture, and method of use | Feb 06, 2026 | King Pharms |
| Skelaxin | US7714006 | Methods of modifying the bioavailability of metaxalone |
Dec 03, 2021
(Expired) | King Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Metaxalone's patents.
Latest Legal Activities on Metaxalone's Patents
Given below is the list recent legal activities going on the following patents of Metaxalone.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 05 Mar, 2024 | US11918559 |
| Recordation of Patent Grant Mailed Critical | 05 Mar, 2024 | US11918559 |
| Patent Issue Date Used in PTA Calculation Critical | 05 Mar, 2024 | US11918559 |
| Mail Patent eGrant Notification | 05 Mar, 2024 | US11918559 |
| Recordation of Patent eGrant | 05 Mar, 2024 | US11918559 |
| Patent eGrant Notification | 05 Mar, 2024 | US11918559 |
| Email Notification Critical | 14 Feb, 2024 | US11918559 |
| Issue Notification Mailed Critical | 14 Feb, 2024 | US11918559 |
| Dispatch to FDC | 05 Feb, 2024 | US11918559 |
| Application Is Considered Ready for Issue Critical | 05 Feb, 2024 | US11918559 |
Metaxalone's Family Patents
Explore Our Curated Drug Screens
Metaxalone Generic API Manufacturers
Several generic applications have been filed for Metaxalone. The first generic version for Metaxalone was by Sandoz Inc and was approved on Mar 31, 2010. And the latest generic version is by Ingenus Pharmaceuticals Llc and was approved on Oct 21, 2020.
Given below is the list of companies who have filed for Metaxalone generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS LABS FL INC
Actavis Laboratories Fl Inc has filed for 1 generic for Metaxalone. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 800MG | tablet | Prescription | ORAL | AB | Jun 15, 2017 |
2. AMNEAL PHARMS
Amneal Pharmaceuticals has filed for 1 generic for Metaxalone. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 800MG
(reference standard) | tablet | Prescription | ORAL | AB | Jun 21, 2013 |
3. INGENUS PHARMS LLC
Ingenus Pharmaceuticals Llc has filed for 1 generic for Metaxalone. Given below are the details of the strengths of this generic introduced by Ingenus Pharms Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 800MG | tablet | Discontinued | ORAL | N/A | Oct 21, 2020 |
4. LANNETT CO INC
Lannett Co Inc has filed for 1 generic for Metaxalone. Given below are the details of the strengths of this generic introduced by Lannett Co Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 800MG | tablet | Prescription | ORAL | AB | Nov 22, 2016 |
5. MOUNTAIN
Mountain Llc has filed for 1 generic for Metaxalone. Given below are the details of the strengths of this generic introduced by Mountain.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 400MG | tablet | Prescription | ORAL | AB | Feb 27, 2015 |
6. RISING
Rising Pharma Holding Inc has filed for 1 generic for Metaxalone. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 800MG | tablet | Prescription | ORAL | BX | Sep 24, 2018 |
Manufacturing Plant Locations New
Rising's manufacturing plants are situated in 3 countries - United States, Mexico, India. Given below are the details of these plant locations as well as the firm names of Rising as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||
| Mexico |
| |||||||||||||||||||
| India |
| |||||||||||||||||||
7. SANDOZ
Sandoz Inc has filed for 1 generic for Metaxalone. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 800MG | tablet | Prescription | ORAL | AB | Mar 31, 2010 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
8. SCIEGEN PHARMS INC
Sciegen Pharmaceuticals Inc has filed for 2 different strengths of generic version for Metaxalone. Given below are the details of the strengths of this generic introduced by Sciegen Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 800MG | tablet | Prescription | ORAL | AB | Aug 31, 2017 |
| 400MG | tablet | Prescription | ORAL | AB | Mar 13, 2020 |